Asia-Pacific journal of clinical oncology最新文献

{"title":"Safety and Efficacy of Lutetium-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study).","authors":"Cherie Wei Qi Ng, Wei Ming Chua, Winnie Wing-Chuen Lam, Aaron Kian-Ti Tong, David Chee Eng Ng, Charlene Yu Lin Tang, Wei Ying Tham, Ravindran Kanesvaran, Alvin Seng Cheong Wong, Kae Jack Tay, Kenneth Chen, Sue Ping Thang","doi":"10.1111/ajco.14195","DOIUrl":"https://doi.org/10.1111/ajco.14195","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate cancer is the second most common cancer and the leading cause of cancer-related deaths in men. Patients with metastatic castration-resistant prostate cancer (mCRPC) with diffuse bone metastases have limited treatment options due to severe hematological toxicity risks. This study evaluates the safety and efficacy of [¹⁷⁷Lu]Lu-PSMA radioligand therapy (RLT) in this high-risk group within an Asian population.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 48 mCRPC patients with PSMA-avid diffuse bone metastases treated with [¹⁷⁷Lu]Lu-PSMA-RLT between May 9, 2018 and Jan 10, 2023. Patients received up to 4 to 6 initial therapy cycles, with additional cycles considered for those who responded initially but later progressed. Primary and secondary endpoints included overall survival (OS), PSA progression-free survival (PFS), PSA response, clinical response, and toxicity assessment.</p><p><strong>Results: </strong>Median OS was 9.3 months. Any PSA response was observed in 75% of patients. Notably, 48% achieved a ≥50% PSA reduction, correlating with a longer median OS (11.6 vs. 8.6 months, p = 0.03). Median PSA PFS was 3.2 months, with improved outcomes observed in patients achieving ≥50% PSA reduction (6.0 vs. 1.8 months, p < 0.0001). Pain relief was reported in 43% of patients, with a median pain score reduction of 5 points. The most common adverse effect was hepatotoxicity, with anemia in 27%, neutropenia in 27%, and thrombocytopenia in 21%.</p><p><strong>Conclusion: </strong>[¹⁷⁷Lu]Lu-PSMA-RLT demonstrates clinically meaningful benefits in survival and symptom management with an acceptable safety profile for mCRPC patients with extensive bone metastases. These findings support [¹⁷⁷Lu]Lu-PSMA-RLT as a viable treatment option for this challenging population.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of IGFL2 Gene Expression and Prognostic Value in Bladder Cancer Based On TCGA Database.","authors":"Xierzhati Aizezi, Bahatiguli Silafu, Yuan Ma, Zheng Wang, Jifu Li, Jinxing Huang","doi":"10.1111/ajco.14191","DOIUrl":"https://doi.org/10.1111/ajco.14191","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer is a prevalent malignant tumor of the urinary system, primarily affecting middle-aged and elderly populations.</p><p><strong>Objective: </strong>To delineate the pathogenic significance of IGFL2 dysregulation and assess its clinical utility as a theranostic biomarker.</p><p><strong>Methods: </strong>Data were retrieved from the TCGA database, whereas complementary datasets were acquired via the Gene Expression Profiling Interactive Analysis (GEPIA), the Human Protein Atlas (THPA), and cBioPortal databases. IGFL2 emerged as a prominently dysregulated gene and was screened by differential expression analysis. Kaplan-Meier survival curves and Cox regression model were used to analyze its relationship with patient survival. The degree of immune cell infiltration and its correlation with IGFL2 were evaluated, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were performed. All statistical analyses were performed using R software, and p < 0.05 was set as significant.</p><p><strong>Results: </strong>IGFL2 expression was significantly upregulated in bladder cancer (p < 0.05), with a diagnostic AUC of 0.828 (95% CI: 0.761-0.896), and was correlated with pathological TNM staging, histological grading, and overall survival (OS) outcomes. Patients with high expression of IGFL2 were associated with poorer OS and disease-specific survival (DSS) (p < 0.05). High expression of IGFL2 was an independent prognostic risk factor (HR = 3.049, 95% CI: 1.592-5.840, p < 0.001). IGFL2 may be involved in signaling pathways such as PI3K-Akt and MAPK. IGFL2 expression was positively correlated with the infiltration levels of macrophages, Th1 cells, and NK cells (p < 0.05).</p><p><strong>Conclusion: </strong>IGFL2 is highly expressed in bladder cancer and may be associated with a poor prognosis. IGFL2 may become a potential biomarker and an important therapeutic target for bladder cancer patients.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Double-Blind Placebo-Controlled Study Comparing Upfront and Subsequent Netupitant in Addition to Olanzapine-Containing Regimen for Prevention of High-Dose Cisplatin-Induced Nausea/Vomiting.","authors":"Chanida Vinayanuwattikun, Chalermchai Lertanansit, Wasamol Mahaparn, Attapol Chotirut, Nicha Zungsontiporn, Suleepon Uttamapinan, Nattaya Sintawichai, Piyada Sitthideatphaiboon, Virote Sriuranpong, Suebpong Tanasanvimon","doi":"10.1111/ajco.14192","DOIUrl":"https://doi.org/10.1111/ajco.14192","url":null,"abstract":"<p><strong>Background: </strong>Addition of olanzapine to NK-1 receptor antagonist regimen improves chemotherapy-induced nausea and vomiting (CINV) prevention for highly emetogenic chemotherapies (HECs). However, the benefit of addition of NK-1 receptor antagonist to olanzapine regimen has not been demonstrated. This study compared the efficacy of upfront and subsequent addition of netupitant- to olanzapine-containing regimen for preventing CINV from high-dose cisplatin (≥ 75 mg/m²).</p><p><strong>Patient and methods: </strong>The double-blind placebo-controlled trial randomized patients receiving high-dose cisplatin to upfront and subsequent netupitant arms. In upfront netupitant arm, patients received NEPA (a combination of netupitant and palonosetron), dexamethasone, and olanzapine since first cycle. In subsequent netupitant arm, patients received olanzapine, dexamethasone, and ondansetron in first cycle but received NEPA, dexamethasone, and olanzapine in second cycle if no complete response (CR). After preplanned analysis, the initial dexamethasone dose in netupitant regimen was modified from 4 to 8 mg on Days 2-4. The primary endpoint was the overall CR rate of two cycles.</p><p><strong>Results: </strong>Between January 2019 and December 2020, 51 and 49 patients were randomly assigned to upfront and subsequent netupitant arms, respectively. CR rates in acute (0-24 h), delayed (> 24-120 h), and overall periods were 93.0% versus 77.4% (p = 0.003), 75.5% versus 68.8% (p = 0.31), and 73.3% and 67.7% (p = 0.34) in upfront and subsequent netupitant arms, respectively. After amendment to increase dexamethasone in netupitant regimen, first-cycle CR rates in acute, delayed, and overall periods were 95.2% versus 87.7% (p = 0.34), 85.7% versus 73.5% (p = 0.26), and 85.7% and 69.4% (p = 0.26) in 4-drug and 3-drug groups, respectively. Among 15 patients crossing over to receive netupitant regimen in second cycle, CR was 46.6%.</p><p><strong>Conclusion: </strong>In this Phase II trial, there was no significant improvement in overall CR when patients received upfront netupitant compared to subsequent addition of netupitant to an olanzapine regimen in patients receiving high-dose cisplatin chemotherapy.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Significance of Circulating Basophils as Predictors of Tumor Aggressiveness in Clear-Cell Renal Cell Carcinoma.","authors":"Burak Arslan, Hakan Ceylan, Oguzhan Cura, Mert Kahraman, Sibel Bektas, Sina Kardas, Mustafa Gökhan Köse, Mücahit Gelmis, Ali Ayten, Ali Güler","doi":"10.1111/ajco.14196","DOIUrl":"https://doi.org/10.1111/ajco.14196","url":null,"abstract":"<p><strong>Aim: </strong>Our aim was to investigate the value of basophils in predicting tumor aggressiveness in clear-cell renal cell carcinoma (ccRCC).</p><p><strong>Methods: </strong>Baseline characteristics of 183 patients were recorded. Receiver operating characteristic (ROC) curve analysis was performed to calculate the cut-off value for basophil count in predicting the presence of perirenal and/or renal sinus fat involvement, as well as a high-grade WHO/ISUP score. Regression analyses were performed to determine the independent risk factors for perirenal/renal sinus fat invasion and a high-grade WHO/ISUP score.</p><p><strong>Results: </strong>The ROC curve analysis showed that the cut-off value of basophil count was 0.045 for the presence of a high-grade WHO/ISUP score (AUC = 0.769) and perirenal and/or renal sinus fat involvement (AUC = 0.731). Tumor size (p = 0.013), high WHO/ISUP grade (p = 0.036), LVI (p = 0.028), perirenal/renal sinus fat involvement (p = 0.043), and advanced (3-4) TNM stage (0.012) were significantly higher in patients with basophil count ≥ 0.045. In multivariate analysis, tumor size (OR = 1.10), LVI (OR = 3.35), and preoperative basophil count ≥ 0.045 (OR = 3.65) were found to be independent predictors for the presence of a high-grade WHO/ISUP score. Similarly, tumor size (OR = 1.21), high WHO/ISUP grade (OR = 2.44), and preoperative basophil count ≥ 0.045 (OR = 1.96) were found to be independent predictors for the presence of perirenal and/or renal sinus fat involvement in multivariate analysis.</p><p><strong>Conclusion: </strong>Our results demonstrated that preoperative basophil count emerges as a valuable predictor of tumor aggressiveness in ccRCC, offering a readily accessible biomarker to aid in the management of this malignancy.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Penpulimab-kcqx-A Breakthrough in Nasopharyngeal Carcinoma Immunotherapy and the Urgent Need for Global Access.","authors":"Muhammad Hassan Umrani","doi":"10.1111/ajco.14198","DOIUrl":"https://doi.org/10.1111/ajco.14198","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Nivolumab-Related Myasthenia Gravis With Pretreatment Positive Anti-Acetylcholine Receptor Antibodies, and a Literature Review.","authors":"Minami Takahashi, Junji Kato, Taro Saito, Kohei Horimoto, Yoshiyuki Matsui, Masaya Tanno, Hisashi Uhara","doi":"10.1111/ajco.14193","DOIUrl":"https://doi.org/10.1111/ajco.14193","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Surgery in Management of Primary Metastatic Endometrial Cancer.","authors":"Taylor Hodge, Monica McGauran, Antonia Jones, Rosemary McBain, Simon Hyde","doi":"10.1111/ajco.14188","DOIUrl":"https://doi.org/10.1111/ajco.14188","url":null,"abstract":"<p><p>For the majority of patients with endometrial cancer who are diagnosed at an early stage, high-quality evidence directs mainstay initial surgical treatment, which confers excellent long-term survival. Conversely, the 8%-15% of endometrial cancers diagnosed at a clinically advanced stage with primary metastatic disease have a significantly worse prognosis and a 5-year relative survival rate of 15%-20%. The management of primary advanced endometrial cancer is understudied with the majority of relevant evidence being retrospective, single institution, and in heterogenous populations (combined with management of recurrent endometrial cancer), and there are few prospective studies that focus solely on primary advanced disease. It appears that hysterectomy and surgical cytoreduction may improve long-term survival in metastatic endometrial cancer; however, it remains unclear which patients are most likely to benefit. Furthermore, the new integration of molecular classifications to the management of endometrial cancer has opened up new prognosis and treatment perspectives; however, the majority of current trials investigating new management paradigms based on molecular features exclude advanced-stage disease, so the implications for practice regarding this patient group are understudied. This review analyzes the current available evidence regarding surgical management of primary metastatic endometrial cancer, including current international guideline recommendations, evidence for primary cytoreductive surgery and neoadjuvant systemic treatment followed by surgery, surgical resection of distant metastases, and lymph node management.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2-Year Post-Marketing Surveillance.","authors":"Yuko Tanabe, Kenichi Inoue, Masato Takahashi, Hirofumi Mukai, Takashi Yamanaka, Chiyomi Egawa, Yohei Uchida, Yoichi Higashibeppu, Yukinori Sakata, Michiko Sugawara, Junji Tsurutani","doi":"10.1111/ajco.14189","DOIUrl":"https://doi.org/10.1111/ajco.14189","url":null,"abstract":"<p><strong>Aim: </strong>Invasive lobular carcinoma (ILC) is the second most common breast cancer type after invasive ductal carcinoma (IDC). Eribulin mesylate (eribulin) is a non-taxane microtubule dynamics inhibitor approved for advanced or metastatic breast cancer, including ILC and IDC. However, real-world data from eribulin-treated patients with advanced or metastatic ILC are scarce.</p><p><strong>Methods: </strong>This post hoc analysis of a Japanese multicenter, prospective, observational post-marketing surveillance (ClinicalTrials.gov: NCT02371174) evaluated data from eribulin-treated patients with ILC or IDC. Overall survival (OS) from the initiation of first-line chemotherapy, OS from the first date of eribulin administration, and time-to-treatment failure (TTF) were evaluated. OS from eribulin initiation was also evaluated by line of eribulin treatment (first-line, second-line, and third-line or later). Adverse drug reactions (ADRs) with ≥ 5% frequency in both groups were evaluated.</p><p><strong>Results: </strong>Among patients with ILC (n = 33) and IDC (n = 543), median OS from the initiation of first-line chemotherapy was 25.5 and 39.0 months, respectively (hazard ratio 1.94 [95% confidence interval 1.28-2.94]; p < 0.05), median OS from the first date of eribulin administration was 16.0 and 18.0 months, respectively (1.31 [0.87-1.97]), and TTF was 6 and 5 months (0.92 [0.65-1.32]). No significant differences were observed in median OS when stratified by line of eribulin treatment. Type and frequency of ADRs did not differ significantly between the groups.</p><p><strong>Conclusion: </strong>OS and TTF after eribulin initiation were similar between ILC and IDC cases, suggesting that eribulin might be a beneficial treatment option for ILC.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-Therapeutic Dosimetry of Metastatic Castration-Resistant Prostate Cancer With ¹⁷⁷Lu-PSMA: Experiences From Two University-Based Hospitals in Thailand.","authors":"Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon-Iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee","doi":"10.1111/ajco.14187","DOIUrl":"https://doi.org/10.1111/ajco.14187","url":null,"abstract":"<p><strong>Objective: </strong>¹⁷⁷Lu-PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration-resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing ¹⁷⁷Lu-PSMA-RLT from two university-based hospitals in Thailand.</p><p><strong>Methods: </strong>We retrospectively analyzed 61 treatment cycles in 36 patients who underwent posttreatment whole-body planar imaging at three time points (1, 24, and 168 h postadministration). Absorbed doses were computed using organ based MIRD (Medical Internal Radiation Dosimetry) method with OLINDA/EXM v.2.2 in Hermes dosimetry software.</p><p><strong>Results: </strong>The median treated activity was 5.79 GBq (range 5.00-7.29 GBq). Normal organ absorbed doses, from lowest to highest, were red marrow (0.03 ± 0.03 Gy/GBq), total body (0.04 ± 0.03 Gy/GBq), liver (0.13 ± 0.33 Gy/GBq), salivary glands (0.65 ± 0.42 Gy/GBq), and kidneys (0.72 ± 0.36 Gy/GBq).</p><p><strong>Conclusion: </strong>Absorbed doses to normal organs remained within an acceptable range and not exceed the tolerance limits.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management Strategies and Outcomes of Tumor Thrombus in Extremity Osteosarcoma.","authors":"Ashik A Bary, Karthigaiselvi Murugesan, Chandra Kumar Krishnan, Shirley SunderSingh, Anand Raja","doi":"10.1111/ajco.14190","DOIUrl":"https://doi.org/10.1111/ajco.14190","url":null,"abstract":"<p><p>Osteosarcoma, accounting for 2.4% of all childhood malignancies and about 20% of primary bone cancers, primarily affects young adults, with 60% of cases occurring before age 25. Tumor thrombus (TT) formation, a type of cancer-associated thrombosis, is a rare but critical complication in osteosarcoma, leading to increased morbidity and mortality. TT is characterized by the direct extension of the tumor into adjacent vessels, displaying similar imaging characteristics and contrast enhancement as the primary tumor. Our study is a case series of five cases of extremity osteosarcoma where the presence of tumor thrombus has been diagnosed, highlighting diagnostic challenges and management strategies. Preoperative identification of TT remains difficult and is often diagnosed postoperatively or at autopsy. Advanced imaging techniques such as Computed Tomography, Magnetic Resonance Imaging, and Positron Emission Tomography can aid in the detection of TT, although they are not definitive. Surgical resection combined with thrombectomy is recommended, improving prognosis. Anticoagulation therapy aims to prevent bland thrombus formation rather than resolving TT, as the latter increases the risk of embolization. This study underscores the need for heightened suspicion and comprehensive preoperative imaging to improve outcomes in osteosarcoma patients with TT, advocating for multidisciplinary management including vascular surgeons during limb salvage procedures. Further research is essential to optimize anticoagulation protocols and validate these findings in larger cohorts.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}